Antibiotic Resistance

Antibiotic Resistance Market is valued at USD 8.23 Billion in 2018 and expected to reach USD 12.05 Billion by 2025 with the CAGR of 5.6% over the forecast period. - Increasing cases of chronic and bacterial infectious disorders and lack of awareness regarding the overuse or misuse of antibiotics are expected to drive the growth of the Global Antimicrobial Resistance Market.
Scope of the Report:
Antibiotic resistance is the ability of microorganisms or other bacteria to resist the effects of an antibiotic. Antibiotic resistance arises when bacteria develops the ability to defeat the drugs designed to kill them. It is accelerated by the overuse of antibiotics, as well as poor infection prevention and control. While there are some new antibiotics in development, none of them are expected to be effective against the primary dangerous varieties of antibiotic-resistant microorganisms. Infections caused by antibiotic-resistant germs are harsh and sometimes impossible to treat. In most of the cases, antibiotic-resistant infections require prolonged hospital visits, additional follow-up doctor visits, and costly and toxic alternatives. For Example, bacteria that are resistant to antibiotics include methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Enterococcus, and multidrug-resistant Mycobacterium tuberculosis (MDR-TB), which are resistant to two tuberculosis drugs, isoniazid, and rifampicin.
Global antibiotic resistance market report is segmented on the basis of disease, pathogen, drug classes and region & country level. Based upon disease, antibiotic resistance market is classified as complicated urinary tract infection, complicated intra-abdominal infections, blood stream infections, clostridium difficile infections, acute bacterial skin and skin structure infections, hospital acquired bacterial pneumonia/ventilator and community acquired bacterial pneumonia. Based upon based upon pathogen, antibiotic resistance market is classified into acinetobacter baumannii, pseudomonas aeruginosa, staphylococcus aureus, e. coli/k. pneumonia, streptococcus pneumonia, clostridium difficile, enterococcus faecium, and haemophilus influenza. Based upon drug classes, market is segmented into oxazolidinones, lipoglycopeptides, tetracycline, cephalosporins, and combination therapies and other.
The regions covered in this Global Antibiotic Resistance market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Antibiotic Resistance market is sub divided into U.S., Mexico, Canada, UK, France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Key Players for Global Antibiotic Resistance Market Report–
Global Antibiotic Resistance market Report covers prominent players are like TPfizer, Merck, Allergan, The Medicines Company, Melinta Therapeutics, Phage Technologies S.A, Tetraphase Pharmaceuticals, Nabriva Therapeutics, Macrolide Pharmaceuticals, Nemesis Bioscience, Westway Health and Others.Increasing Cases of Chronic and Bacterial Infectious Disorders and Lack of Awareness Regarding the Overuse or Misuse of the Antibiotics are Expected to Drive the Growth of Antimicrobial Resistance Market.
Increasing burden of antibiotic-resistant infections and the development of multi-drug resistant pathogens are expected to increase the growth of antimicrobial resistance market. Increasing antibiotic-resistant infections is mainly occurring due to poor infection control, lacking healthy environments and inappropriate food-handling. For example; WHO’s new Global Antimicrobial Surveillance System (GLASS) reveals that widespread occurrence of antibiotic resistance among 500,000 people with suspected bacterial infections across 22 countries. The most commonly reported resistant bacteria were Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus pneumoniae, followed by Salmonella spp.
In addition, most of the drugs currently in the clinical pipeline are modifications of existing classes of antibiotics and are only instant solutions. According to world health Organization, some of them cause common infections such as pneumonia or urinary tract infections that are increasingly resistant to existing antibiotics and directly require the new treatments. However, time taken for regulatory approval may hamper the growth of the antibiotic resistance market. Increasing development of novel combination of therapies to treat antibiotic-resistant microbial infections can provide new opportunities for the antibiotic resistance market in the forecast period.
Asia Pacific is Expected to Dominate the Global Antibiotic Resistance Market.
Asia Pacific is expected to dominate the global antibiotic resistance market owing to increasing prevalence of bacterial infection in this region. North America and Europe are expected to follow the Asia Pacific in this market. The highly developed medical facilities in North America are one of the factors driving the market growth in this region. According to the World Health Organization, Currently in the U.S., 2 million people are infected with antibiotic-resistant bacteria, and at least 23,000 people die. And Drug-resistant infections already claim 700,000 lives a year, including 230,000 deaths from drug-resistant tuberculosis.
Key Benefits for Global Antibiotic Resistance market Report–
Global market report covers in depth historical and forecast analysis.
Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
Global market report helps to identify opportunities in market place.
Global market report covers extensive analysis of emerging trends and competitive landscape.
Antibiotic Resistance market Segmentation:–
By Disease:
Complicated Urinary Tract Infection
Complicated Intra-Abdominal Infections
Blood Stream Infections
Clostridium difficile infections
Acute Bacterial Skin and Skin Structure Infections
Hospital Acquired Bacterial Pneumonia/Ventilator
Community Acquired Bacterial Pneumonia
By Pathogen:
Acinetobacter baumannii
Pseudomonas aeruginosa
Staphylococcus Aureus
coli/K. pneumoniae
Streptococcus pneumoniae
Clostridium difficile
Enterococcus faecium
Haemophilus Influenzae
By Drug Class:
Oxazolidinones
Lipoglycopeptides
Tetracyclines
Cephalosporins
Combination therapies
Other
By Regional & Country Analysis:
North America
US.
Canada
Europe
UK
France
Germany
Italy
Asia Pacific
China
Japan
India
Southeast Asia
Latin America
Brazil
Mexico
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa

Interested in this report?

Get your sample now!

Download Sample